Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Multiple Sclerosis and Pregnancy: Current Considerations.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
New Drugs Online report for idebenone
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Merck: Regulatory Update on Cladribine Tablets
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.

Pages